Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.

Papadopoulou, Charalampia; Hong, Ying; Omoyinmi, Ebun; Brogan, Paul A; Eleftheriou, Despina

Papadopoulou, Charalampia; Hong, Ying; Omoyinmi, Ebun; Brogan, Paul A; Eleftheriou, Despina.

Afiliación

Papadopoulou C; Infection, Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, London, UK.
Hong Y; Infection, Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, London, UK.
Omoyinmi E; Infection, Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, London, UK.
Brogan PA; Infection, Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, London, UK.
Eleftheriou D; Infection, Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, London, UK.

Brain ; 142(3): e8, 2019 03 01.

Article en En | MEDLINE | ID: mdl-30715143

Asunto(s)

Dermatomiositis; Interferón Tipo I; Inhibidores de las Cinasas Janus; Azetidinas; Humanos; Janus Quinasa 1; Purinas; Pirazoles; Sulfonamidas

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Interferón Tipo I / Dermatomiositis / Inhibidores de las Cinasas Janus Límite: Humans Idioma: En Revista: Brain Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google